On New Year’s Eve, Elon Musk set a manufacturing target for a technology that had reached only a small number of human volunteers. His company, Neuralink, would begin “high-volume production” of brain-computer interfaces in 2026, he said, while moving toward an “entirely automated” surgical procedure. The announcement, reported by Reuters, described an ambition—not evidence that mass implantation or fully autonomous surgery had begun.
A Production Pledge After Twelve Human Implants
The proposed expansion follows less than two years of human trials. Neuralink implanted its first participant in January 2024, after receiving permission for clinical testing in 2023; federal regulators had rejected an earlier application over safety concerns. That authorization permitted research, not commercial marketing. As of September 2025, Neuralink reported 12 people implanted worldwide, all with severe paralysis. Together, they had logged more than 15,000 hours of device use.
The device, called the N1, translates electrical signals associated with intended movement into commands for computers and other equipment. Its 1,024 electrodes are distributed along 64 exceptionally thin threads implanted in the brain. According to Neuralink’s technical documentation, the company already uses a robot, known as R1, to insert those threads—an exacting task that human hands cannot readily perform. But its published surgical description also assigns essential steps to a neurosurgeon: exposing the brain, securing the implant and closing the scalp. Musk’s proposal would extend automation beyond that existing division of labor.
For Noland Arbaugh, the first recipient, the practical benefit has been substantial. Paralyzed below his shoulders after a swimming accident, he previously relied on a mouth-held stylus to use a tablet. With Neuralink, he has played games, browsed the internet and controlled a cursor independently.
Yet several weeks after implantation, some electrode threads retracted, weakening his control. Engineers adjusted the software, restoring much of its function. In a 2024 interview with WIRED, Arbaugh recalled noticing immediately that something was wrong as the cursor became harder to move.
That episode underscores what a production target cannot measure: how an implant performs inside one particular brain over time. Neuralink raised $650 million in June 2025 and expanded its clinical studies, but Musk's announcement did not specify a manufacturing volume or explain how responsibilities during an automated operation would be divided among software developers, surgeons and hospitals.
Neuralink's clinical-trial brochure describes approximately 18 months of primary research followed by five years of follow-up visits. Whether those arrangements could adequately support a much larger population over decades remains unanswered.
Writing in Bioethics, medical student Arturo Balaguer Townsend identified the possible gains of autonomous neurosurgery, including precision, alongside unresolved questions about liability and the loss of human surgical expertise. The concern is especially consequential when an error cannot be corrected by simply restarting a machine.
Surgery Can Scale Faster Than Lifelong Care
For a generation accustomed to software updates, broken screens and devices replaced every few years, the idea of an implant raises an unfamiliar possibility: what if a technology becomes essential to your independence but remains subject to someone else’s product cycle?
The concern is already present in student conversations. In a March 2025 University of Southern California podcast, third-year computer engineering student Michael Wang and host Deep Shah discussed brain-computer interfaces’ promise alongside the risks of hacking, privacy violations and unequal access. Their questions point beyond whether an implant functions. Who controls the infrastructure that keeps it functioning—and on what terms?
Arbaugh’s story complicates any easy answer. By August 2025, he had returned to college coursework, describing a recovered sense of possibility through the implant. But when WIRED asked in 2024 whether Neuralink had offered him an upgraded device, he replied, “I would love one, but they haven’t promised me anything.” His experience makes the difference between access and durable autonomy unusually clear.
There is precedent for that distinction. An IEEE Spectrum investigation documented how people with Second Sight retinal implants struggled to obtain repairs and support after the manufacturer stopped making the devices. And a 2024 JAMA Network Open expert consensus proposed that neurological-device abandonment can include failure to provide reasonable medical, technical or financial support before a device’s stated lifetime ends.
An implant therefore creates a peculiar asymmetry: a patient consents to surgery at one moment, while the conditions governing its usefulness may be revised for years afterward, often without the patient’s participation.
Automation could eventually bring an empowering technology to more people. But each additional recipient would also acquire years of dependence on repairs, software, clinicians and corporate decisions. A machine may someday make implantation routine. The obligation to remain available afterward cannot be automated away.
Explore more exclusive insights at nextfin.ai.
